In 2014, Finland's pharma market saw steady development

16 February 2015

Last year, the pharmacy and hospital sectors of the Finnish pharmaceutical market grew relatively steadily, at about 5%, according to the country’s research-based drug industry association PIF.

The growth of the pharmacy market is explained by the advanced pharmacotherapies that allow more patients with severe diseases to stay and be cared for at home, instead of the expensive hospital care. The 5% cut of the prices of reimbursable original medicines, implemented in 2013, also boosted the growth of the pharmacy market by affecting the calculatory growth figures in 2014.

Measured in wholesale prices, the overall value of the Finnish pharmaceutical market was 2.2 billion euros ($2.5 billion) in 2014.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK